US Pharma MarketingThe post Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial appeared first on Clinical Trials Arena.
Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial
Celldex’s stock is expected to drop when markets open on 22 July following the trial’s failure. The post Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial appeared first on Clinical Trials Arena .
Celldex’s stock is expected to drop when markets open on 22 July following the trial’s failure.
Source: Clinical Trials Arena